tiprankstipranks
Trending News
More News >
Aldeyra Therapeutics: Promising Pipeline and Strategic Focus Justify Buy Rating Despite FDA Concerns
PremiumRatingsAldeyra Therapeutics: Promising Pipeline and Strategic Focus Justify Buy Rating Despite FDA Concerns
11d ago
Aldeyra Therapeutics: Buy Rating Affirmed Amid Promising Developments and Robust Financial Health
Premium
Ratings
Aldeyra Therapeutics: Buy Rating Affirmed Amid Promising Developments and Robust Financial Health
14d ago
Aldeyra Therapeutics Receives FDA Complete Response Letter
Premium
Company Announcements
Aldeyra Therapeutics Receives FDA Complete Response Letter
14d ago
Aldeyra options imply 29.5% move in share price post-earnings
PremiumThe FlyAldeyra options imply 29.5% move in share price post-earnings
22d ago
Aldeyra options imply 30.8% move in share price post-earnings
Premium
The Fly
Aldeyra options imply 30.8% move in share price post-earnings
29d ago
Aldeyra Therapeutics: Buy Rating Affirmed on Promising Reproxalap and Strategic RASP Market Expansion
Premium
Ratings
Aldeyra Therapeutics: Buy Rating Affirmed on Promising Reproxalap and Strategic RASP Market Expansion
1M ago
Optimistic Buy Rating for Aldeyra Therapeutics Amid Promising FDA Review and Potential AbbVie Collaboration
PremiumRatingsOptimistic Buy Rating for Aldeyra Therapeutics Amid Promising FDA Review and Potential AbbVie Collaboration
2M ago
Oppenheimer pharmaceuticals analysts hold analyst/industry conference call
Premium
The Fly
Oppenheimer pharmaceuticals analysts hold analyst/industry conference call
5M ago
Aldeyra says FDA accepts reproxalap NDA,  AbbVie deal expanded to $100M
Premium
The Fly
Aldeyra says FDA accepts reproxalap NDA, AbbVie deal expanded to $100M
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100